THE 5-SECOND TRICK FOR TRASTUZUMAB ANNS

One of the more underneath-investigated “driving forces” associated with trastuzumab resistance is PTEN. Nagata et al. (2004) reported the lack of PTEN was noticed in 36% of HER2-beneficial Major breast tumor specimens from individuals with stage IV disorder. In addition, In addition they showed that people with PTEN-deficient tumors had remark